Share chart Indaptus Therapeutics, Inc.
Extended chart
Simple chart
About
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. more details| IPO date | 2015-08-04 |
|---|---|
| ISIN | US45339J1051 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://indaptusrx.com |
| Цена ао | 2.8 |
| Change price per day: | -1.66% (0.85) |
|---|---|
| Change price per week: | -10.88% (0.938) |
| Change price per month: | -18.84% (1.03) |
| Change price per 3 month: | -35.7% (1.3) |
| Change price per half year: | -61.3% (2.16) |
| Change price per year: | -52.51% (1.76) |
| Change price per 3 year: | -85.1% (5.61) |
| Change price per 5 year: | +70.59% (0.49) |
| Change price per 10 year: | 0% (0.8359) |
| Change price per year to date: | -16.41% (1) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Group Inc | 256265 | 3 |
| Investment House, LLC | 102437 | 1.2 |
| Geode Capital Management, LLC | 54767 | 0.64 |
| Strategy Asset Managers Llc | 45336 | 0.53 |
| Pine Valley Investments Ltd Liability Co | 44240 | 0.52 |
| Renaissance Technologies, LLC | 29400 | 0.34 |
| Vivaldi Capital Management Lp | 24000 | 0.28 |
| State Street Corporation | 19473 | 0.23 |
| Citadel Advisors Llc | 16518 | 0.19 |
| Tower Research Capital LLC (TRC) | 4696 | 0.05 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Jeffrey A. Meckler | CEO & Director | 867.03k | 1967 (58 years) |
| Mr. Walt Addison Linscott Esq. | Chief Operating Officer | 716.35k | 1961 (64 years) |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | 659.99k | 1956 (69 years) |
| Mr. Nir Sassi | CFO, Secretary & Treasurer | 378.47k | 1976 (49 years) |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer | N/A | 1968 (57 years) |
Address: United States, New York. NY, Three Columbus Circle - open in Google maps, open in Yandex maps
Website: https://indaptusrx.com
Website: https://indaptusrx.com
